[stock-ticker]
Home » Archive by Category

Syndication

Genomic Health Announces Presentation of Seven Oncotype DX® Studies at the 2016 American Society of Clinical Oncology Annual Meeting, Including Additional Prospective Outcomes Analysis

May 26, 2016 – 5:00 am

Presentations in Breast and Prostate Cancers Underscore Genomic Health’s Industry-leading Commitment to Help Physicians and Patients Optimize Cancer Treatment Decisions

REDWOOD CITY, Calif., May 26, 2016 /PRNewswire/ — Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will present results from seven Oncotype DX® studies at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, which will take place June 3-7 at McCormick Place in Chicago. The results will include:

  • Four sub-analyses from the large population-based observational study based on the Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Institute (NCI). Highlights include two independent presentations by the SEER-NCI investigators revealing significant disparities in the use of Oncotype DX in patients with early-stage invasive breast cancer. The primary SEER Registry study results, presented at the CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) in December 2015, demonstrated that Oncotype DX accurately predicts prospective patient outcomes in more than 42,000 patients, including those with node-negative and node-positive breast cancer.
  • An oral presentation on the clinical use of the Oncotype DX Breast Recurrence Score™ and patient experiences in invasive breast cancer, led by investigators at the University of Michigan;
  • Five-year clinical outcomes results from the prospective Phase III PlanB trial, one of the largest contemporary adjuvant breast cancer trials in Europe, conducted by the West German Study Group (WSG); and
  • A study of the Oncotype DX Genomic Prostate Score in men with surgically treated intermediate- and high-risk prostate cancer.

“Results from the latest breast and prostate cancer studies highlight the important impact of Oncotype DX in changing the treatment paradigm for hundreds of cancer patients every day,” said Steven Shak, M.D., chief scientific officer, Genomic Health. “The breadth and strength of evidence for the clinical utility of Oncotype DX continue to be uniquely recognized by leading authorities in cancer. For example, the National Comprehensive Cancer Network (NCCN), in its updated breast cancer guidelines regarding node-negative and node-positive patients, specifically named Oncotype DX as the ‘best validated’ test for chemotherapy prediction.”

The ASCO abstracts are now available at http://abstracts.asco.org/. Following are details for each presentation (all times are in Central Daylight Time):

Saturday, June 4

  • Abstract: 6575
    Poster Session: Health Services Research and Quality of Care
    Title: “Breast cancer specific survival in patients with node positive hormone receptor positive invasive breast cancer and Oncotype DX Recurrence Score results in the SEER database”
    Authors: Megan Roberts, Ph.D.
    Location: Hall A
    Time: 1-4:30 p.m.
  • Abstract: 5049
    Poster Session: Genitourinary (Prostate Cancer)
    Title: “A 17-gene genomic prostate score (GPS) as a predictor of biochemical (BCR) and clinical recurrence (CR) in men with surgically treated intermediate- and high-risk prostate cancer (PCa)”
    Authors: Eric A. Klein, M.D.
    Location: Hall A
    Time: 1-4:30 p.m.
  • Abstract: 6552
    Poster Session: Health Services Research and Quality of Care
    Title: “Compliance with guidelines and factors associated with ordering the 21-gene breast cancer assay”
    Author: Valentina I. Petkov, M.D., M.P.H.
    Location: Hall A
    Time: 1-4:30 p.m.
  • Abstract: 6553
    Poster Session: Health Services Research and Quality of Care
    Title: “Dissemination of 21-gene assay testing among female breast cancer patients in the US”
    Authors: Kathleen Cronin, Ph.D., M.P.H.
    Location: Hall A
    Time: 1-4:30 p.m.

Sunday, June 5

  • Abstract: 556
    Poster Session: Breast Cancer – HER2/ER
    Title: “Prognostic impact of 21-Gene Recurrence Score, IHC4, and central grade in high-risk HR+/HER2− early breast cancer (EBC): 5-year results of the prospective Phase III WSG PlanB trial”
    Authors: Oleg Gluz, M.D.
    Location: Hall A
    Time: 8-11:30 a.m.
  • Abstract: 574
    Poster Session: Breast Cancer – HER2/ER
    Title: “Outcome disparities by age and 21-gene recurrence score (RS) in hormone receptor positive (HR+) breast cancer (BC)”
    Authors: Valentina I. Petkov, M.D., M.P.H.
    Location: Hall A
    Time: 8-11:30 a.m.

Monday, June 6

  • Abstract: 6501
    Oral Session: Health Services Research and Quality of Care
    Title: “Clinical use of the 21-gene assay and patient experiences in early-stage breast cancer”
    Author: Steven J. Katz, M.D., M.P.H.
    Location: S100a
    Session Time: 9:45 a.m.-12:45 p.m.
    Oral Presentation Time: 9:57-10:09 a.m.

About Oncotype DX®
The Oncotype DX® portfolio of breast, colon and prostate cancer tests applies advanced genomic science to reveal the unique biology of a tumor in order to optimize cancer treatment decisions. With more than 600,000 patients tested in more than 90 countries, the Oncotype DX tests have redefined personalized medicine by making genomics a critical part of cancer diagnosis and treatment. To learn more about Oncotype DX tests, visit www.OncotypeDX.com, www.mybreastcancertreatment.org and www.myprostatecancertreatment.org.

About Genomic Health 
Genomic Health, Inc. (NASDAQ: GHDX) is the world’s leading provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of cancer, one of the greatest issues in healthcare today. With its Oncotype IQ™ Genomic Intelligence Platform, the company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of clinical and genomic big data into actionable results for treatment planning throughout the cancer patient journey, from diagnosis to treatment selection and monitoring. The Oncotype IQ portfolio of genomic tests and services currently consists of the company’s flagship line of Oncotype DX gene expression tests that have been used to guide treatment decisions for more than 600,000 cancer patients worldwide. Genomic Health is expanding its test portfolio to include additional liquid and tissue-based tests. The company is based in Redwood City, California, with international headquarters in Geneva, Switzerland. For more information, please visit, www.GenomicHealth.com and follow the company on Twitter: @GenomicHealthFacebookYouTube and LinkedIn.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties are set forth in our filings with the Securities and Exchange Commission, including in our quarterly report on Form 10-Q for the quarter ended March 31, 2016. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.

NOTE: The Genomic Health logo, Oncotype, Oncotype DX, Recurrence Score, DCIS Score, Oncotype SEQ, and Oncotype IQ are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.

GHDX-B

Logo – http://photos.prnewswire.com/prnh/20130425/SF01493LOGO

 

SOURCE Genomic Health, Inc.

Tocagen Announces Presentations at the 2016 BIO International Convention and Boston CEO Conference

May 26, 2016 – 5:00 am

SAN DIEGO, May 26, 2016 /PRNewswire/ — Tocagen Inc., a clinical-stage, cancer-selective gene therapy company, today announced members of the company’s management team will participate on a panel discussing the intersection of immuno, viral and gene-based therapies for cancer treatment and present a corporate overview at the 2016 BIO International Convention, to be held June 6-9 in San Francisco.

In addition, Tocagen will participate in a panel discussion at the Boston CEO Conference, to be held May 31-June 1 in Boston, providing insight into the promises and challenges of gene therapy.

Details of the panel and presentation at the 2016 BIO International Convention are as follows:

Panel Title: Lighting the Match on Cancer: The Intersection of Immuno, Viral and Gene Therapy and the Implications for Cancer Treatment 
Date and Time: Thursday, June 9, 9:00-10:15 a.m. PT
Location: West 3002
Participant: Asha Das, M.D., vice president, clinical development and medical affairs at Tocagen

Title: Tocagen Inc. Company Presentation
Date and Time: Wednesday, June 8, 5:00-5:13 p.m. PT
Location: Room 4
Speaker: Nicholas Boyle, Ph.D., vice president, business development and marketing at Tocagen

Details of the panel at Boston CEO Conference are as follows:

Panel Title: Genetic Therapies: The Promise and The Challenge
Date and Time: Wednesday, June 1, 1:30-2:00 p.m. ET
Participant: Harry Gruber, M.D., president and chief executive officer of Tocagen

About Tocagen

Tocagen is a clinical-stage, cancer-selective gene therapy company focused on developing first-in-class, broadly applicable product candidates designed to activate a patient’s immune system against their own cancer from within. The company is developing its lead investigational product candidate, Toca 511 (vocimagene amiretrorepvec) & Toca FC (extended-release 5-fluorocytosine), initially for the treatment of recurrent high grade glioma (HGG), a disease with significant unmet medical need. Tocagen has initiated the Phase 2 portion of a randomized, controlled Phase 2/3 clinical trial of Toca 511 & Toca FC in patients with recurrent HGG, which is designed to serve as a potential registrational trial. More information about the clinical trial can be found at www.tocagen.com/toca5. In 2016, Tocagen plans to initiate clinical trials of Toca 511 & Toca FC in patients with metastatic colorectal, pancreatic, breast, lung, renal and melanoma cancers and in patients with newly diagnosed HGG. Tocagen obtained Fast Track designation from the U.S. Food and Drug Administration, for Toca 511 & Toca FC for the treatment of recurrent HGG and Orphan drug designation for the treatment of glioblastoma (GBM), a subset of HGG. Tocagen has received grant support from leading brain cancer foundations, including Accelerate Brain Cancer Cure (ABC2), National Brain Tumor Society (NBTS), American Brain Tumor Association (ABTA), Musella Foundation and Voices Against Brain Cancer (VABC). For more information, visit www.tocagen.com or follow @Tocagen.

 

SOURCE Tocagen Inc.

Sorrento Therapeutics to Present at the Jefferies 2016 Healthcare Conference

May 26, 2016 – 4:00 am

SAN DIEGO, May 26, 2016 /PRNewswire/ — Sorrento Therapeutics, Inc. (NASDAQ: SRNE; “Sorrento”), an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other unmet medical needs, announced today that Dr. Henry Ji, President and CEO, will present at the Jefferies 2016 Healthcare Conference on Thursday, June 9, 2016 in New York, NY.  The Sorrento presentation is scheduled to begin at 9:00am EDT

About Sorrento Therapeutics, Inc. 

Sorrento is an antibody-centric, clinical stage biopharmaceutical company developing new treatments for cancer, inflammation and autoimmune diseases. Sorrento’s lead products are multiple late-stage biosimilar and biobetter antibodies, as well as clinical CAR-T therapies targeting solid tumors.

Forward-Looking Statements

This press release and any statements made for and during any presentation or meeting contain forward-looking statements related to Sorrento Therapeutics, Inc., and its subsidiaries under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements regarding the announcement or consummation of any strategic alternatives and any related transactions; the expected closing of the additional private placements; Sorrento’s proposed joint venture with Yuhan; Sorrento’s and its subsidiaries’ prospects; Sorrento’s expectations for its technologies and collaborations; Sorrento’s and its subsidiaries’ advances made in developing antibody drug conjugates (ADCs), human monoclonal antibodies using its proprietary G-MAB fully human antibody technology and any of their other respective technologies, if any; and other matters that are described in Sorrento’s Annual Report on Form 10-K for the year ended December 31, 2015, as amended, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, including the risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release and we undertake no obligation to update any forward-looking statement in this press release except as required by law.

Sorrento® and the Sorrento logo are registered trademarks of Sorrento Therapeutics, Inc.

All other trademarks and trade names are the property of their respective owners.

© 2016 Sorrento Therapeutics, Inc.  All Rights Reserved.

Logo – http://photos.prnewswire.com/prnh/20150105/167173LOGO  

 

SOURCE Sorrento Therapeutics, Inc.

Sr. Manager Finance, Forecasting (Pharmaceuticals) – San Diego Biosciences – San Diego, CA

May 25, 2016 – 7:48 pm

We are a successful San Diego Bioscience company that discovers and develops innovative and life-changing pharmaceuticals, in diseases with high unmet medical
From Indeed – 26 May 2016 02:48:10 GMT
– View all San Diego jobs

Clinical Laboratory Technician (Calsbad)

May 25, 2016 – 3:59 pm

Exciting opportunity in a team focusing on neuro endocrine research.
We are currently utilizing state of the art technologies (LC/MS/MS and Dynex Elisa System) to identify amino acids, neurotransmitters, metabolites and hormones for brain chemistry […

Scientific Systems Analyst – Eli Lilly – San Diego, CA

May 25, 2016 – 3:46 pm

This position is in Lilly’s Research IT organization focused on the full lifecycle of scientific applications from requirements gathering to software
From Eli Lilly – 25 May 2016 22:46:57 GMT
– View all San Diego jobs

MARCOM Associate – Part-time/Temp to hire – ACON Laboratories, Inc. – San Diego, CA

May 25, 2016 – 3:36 pm

Participate in the design of the promotional materials, and work in conjunction with Corporate Account Managers to support execution of – and measurement of -…
From Indeed – 25 May 2016 22:36:08 GMT
– View all San Diego jobs

Production Development Scientist

May 25, 2016 – 2:55 pm

The Scientist in the Product Development Department initiates, directs and executes all preclinical scientific research and/or development strategies for a company through the research staff or individual studies.
*Will be leading a team of research […

Oncology Research Associate I – Tanabe Research Laboratories – San Diego, CA

May 25, 2016 – 2:41 pm

Tanabe Research Laboratories USA located in San Diego, California is a cutting edge biotechnology company dedicated to the discovery and advancement of…
From DeviceSpace.com – 25 May 2016 21:41:37 GMT
– View all San Diego jobs

Seeking Molecular Biology Research Associates (San Diego)

May 25, 2016 – 2:33 pm

Seeking a Molecular Biology Research Associate. All lab work!
JOB DESCRIPTION
Performing PCR, pippetting, QC, NGS
Effectively and efficiently test raw materials, in-process and final product and generate testing data.
Conduct and maintain the rea […